Skip to content

Arvinas ARVN Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's accrued progress collections and price adjustments?
Arvinas (ARVN) reported accrued progress collections and price adjustments of $138.2M in Q1 2026.
How has Arvinas's accrued progress collections and price adjustments changed year-over-year?
Arvinas's accrued progress collections and price adjustments increased by 16.7% year-over-year, from $118.4M to $138.2M.
What is the long-term trend for Arvinas's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), Arvinas's accrued progress collections and price adjustments has grown at a 42.4% compound annual growth rate (CAGR), from $22.9M to $134.3M.